Business Context and Reporting Period
This Form 6-K filing by MDxHealth SA covers the month of July 2026, with the report dated July 2, 2026. The Company is a foreign private issuer listed on The Nasdaq Capital Market. The filing primarily addresses a regulatory notice received on June 30, 2026, regarding non-compliance with Nasdaq listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and listing status rather than financial performance data.
Material Changes
- Stock Price Non-Compliance: The Company received notice from Nasdaq that its ordinary shares closed below $1.00 per share for 30 consecutive trading days, violating Listing Rule 5550(a)(2).
- Compliance Period: Nasdaq granted an Initial Compliance Period of 180 calendar days, ending December 28, 2026, to regain compliance.
- Remediation Requirement: To cure the deficiency, the closing bid price must meet or exceed $1.00 per share for a minimum of 10 consecutive trading days prior to the December 28, 2026 deadline.
Outlook, Risks, and Management Commentary
Management is currently evaluating various courses of action to regain compliance but stated there can be no assurance that compliance will be achieved within the Initial Compliance Period. If the Company fails to regain compliance by December 28, 2026, it may be eligible for an additional 180-day grace period, provided it meets the market value of publicly held shares requirement and other initial listing standards.
Risks and Contingencies:
- Delisting Risk: Failure to cure the deficiency could result in delisting from Nasdaq.
- Capital Raising: Non-compliance or delisting would materially and adversely affect the Company's ability to raise capital and its overall financial condition.
- Resource Diversion: Addressing the non-compliance may incur substantial costs and divert personnel attention from core business operations.
Investor Verification Checklist
- Verify the current closing bid price of MDxHealth SA ordinary shares to assess proximity to the $1.00 threshold.
- Monitor the Company's stock price performance over the next 10 consecutive trading days to determine if the cure requirement is met.
- Review future filings for announcements regarding a reverse stock split or other capital structure changes intended to address the bid price deficiency.
- Check the Company's market value of publicly held shares to determine eligibility for a potential second compliance period if the initial deadline is missed.